Table 4 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings

作者：James J. Harding, Ralf‐Dieter Hofheinz, Elena Élez, Yasutoshi Kuboki, Drew Rasco, Michael Cecchini, Lin Shen, Min He, Shorena Archuadze, Niraj Chhaya, Franziska Haderk, Lisa Mészáros, Stefan Wölke, Tetsuya Katakabe, Robert M. Lorence, Eric Van Cutsem, Scott Kopetz, Shubham Pant · 年份：2026 · DOI：10.1158/2767-9764.32700245 · 研究领域：HER2/EGFR in Cancer Research、Colorectal Cancer Treatments and Studies、PARP inhibition in cancer therapy

<p>Pharmacokinetic parameters for BI 905711 as monotherapy (NCT04137289)<a href="#t4n1" target="_blank"><sup>a</sup></a>.</p>